Cargando…
An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion
Spencer Phillips Hey and Aaron Kesselheim propose that informativeness—asserting scientific facts—rather than truthfulness ought to be the standard for regulating commercial speech about pharmaceuticals.
Autores principales: | Hey, Spencer Phillips, Kesselheim, Aaron S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792458/ https://www.ncbi.nlm.nih.gov/pubmed/26978686 http://dx.doi.org/10.1371/journal.pmed.1001978 |
Ejemplares similares
-
Off-Label Promotion, On-Target Sales
por: Fugh-Berman, Adriane, et al.
Publicado: (2008) -
ENGAGE and EMERGE: Truth and consequences?
por: Kuller, Lewis H., et al.
Publicado: (2021) -
Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
por: Kesselheim, Aaron S., et al.
Publicado: (2017) -
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures
por: Brown, Beatrice L., et al.
Publicado: (2023) -
Informed Consent and Shared Decision-Making: A Requirement to Disclose to Patients Off-Label Prescriptions
por: Wilkes, Michael, et al.
Publicado: (2008)